Flex Pharma Inc (NASDAQ:FLKS) has been downgraded to Hold in a statement by Cantor Fitzgerald earlier today.
- Updated: October 14, 2016
Cantor Fitzgerald has downgraded Flex Pharma Inc (NASDAQ:FLKS) to Hold in a report released on Friday October 14, 2016.
On 4/12/2016, Roth Capital released a statement on Flex Pharma Inc (NASDAQ:FLKS) lowered the target price from $27.00 to $24.00. At the time, this indicated a possible upside of 1.17%.
Only yesterday Flex Pharma Inc (NASDAQ:FLKS) traded -6.29% lower at $8.43. FLKS’s 50-day average is $11.29 and its two hundred day moving average is $11.38. The last closing price is down -30.56% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 16,406 shares of FLKS traded hands, down from an average trading volume of 51,629
Recent Performance Chart
Flex Pharma Inc has with a one year low of $6.48 and a one year high of $13.97 and has a total market value of $0.
In addition to Cantor Fitzgerald reporting its stock price target, a total of 6 brokerages have released a research note on FLKS. The one year target is $27.00 with one firm rating the stock a strong buy, 5 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokerages rating the company a underperform, and lastly zero equity analysts rating the company a sell.
Brief Synopsis About Flex Pharma Inc (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.